BOSTON--(BUSINESS WIRE)--Tectonic Therapeutic today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
“Tectonic is thrilled to be distinguished as a Fierce 15 company, recognizing our pursuit of novel GPCR-targeted therapies,” said Alise Reicin, MD, President and Chief Executive Officer, Tectonic Therapeutic. “At Tectonic, we have harnessed the pioneering work of our academic founders and assembled a team of industry experts to advance a biologic approach via our GEODeTM platform to address important unmet clinical needs. We look forward to continued momentum during this transformative time for the Company.”
Tectonic’s novel approach has the potential to unlock the full therapeutic utility of GPCRs. GCPRs are central to human biology and are the target of approximately a third of all approved drugs for treating a wide range of diseases. Yet, GPCRs remain a large untapped opportunity as many receptors remain unexplored or are undruggable by small molecules. Instead of using small molecules, Tectonic is taking a biologic approach with their GEODe™ platform that is designed to overcome the challenges encountered to date in GPCR biologic discovery campaigns. A biologic approach will address major challenges by increasing specificity and by facilitating the targeting of GPCRs whose natural ligands are peptides or proteins.
“In 2020, we got to celebrate the best and brightest biotechs trying to dig the world out of the pandemic. Speaking with this year’s class of Fierce 15 winners showed us that not even a global pandemic can stop incredible innovations in medicine, and we’re on the cusp of some new breakthrough treatments that have continued apace despite unprecedented disruption last year,” said Annalee Armstrong, Senior Editor of Fierce Biotech. “Slowing down was not an option for our 2021 Fierce 15 winners. From a biotech exploring a new type of viral vector for gene therapies to one trying to crack fibroblasts as a way to target resistant tumors, the Fierce Biotech team heard one thing in common: strong teams of scientists and professionals united in a goal to advance life-changing medicines. We’re proud to showcase this esteemed group of emerging biotechs to the world.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech’s 19th annual Fierce 15 selection.
An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day's top stories. Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
About Fierce Biotech
Fierce Biotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biopharma professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.
About Tectonic Therapeutic
Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. With our proprietary GEODe platform, we aim to unlock the therapeutic utility of the most difficult receptors in the class, to date considered undruggable with small molecules. For more information, please visit www.tectonictx.com, or follow us on LinkedIn.